Predicting lymphovascular invasion in pancreatic cancer patients before surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a preoperative model to predict lymphovascular invasion (LVI) in patients diagnosed with pancreatic ductal adenocarcinoma (PDAC). By analyzing data from patients at three tertiary hospitals, the researchers will use univariate and multivariate logistic regression to identify independent predictors of LVI. A nomogram will be created based on these findings, and its predictive accuracy will be evaluated using ROC curves and calibration plots. The study seeks to provide a tool that could help guide treatment decisions for PDAC patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who were pathologically diagnosed as PDAC and received curative surgery.

Exclusion Criteria:

* Patients with distant metastasis; Patients who received neoadjuvant therapy; Patients with a survival time of less than 1 month.

Where it's running

• Tianjin Medical University Cancer Institute and Hospital
  Tianjin, Tianjin, China Recruiting

Study contacts

• Study coordinator: Jihui Hao, Dr
• Email: haojihui@tjmuch.com
• Phone: +8618622221120

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• INSPIRE: Putting patient-reported info into multidisciplinary tumor boards

  This study tests whether adding electronic patient-reported outcomes to tumor board discussions can help guide treatment decisions for women with breast, gynecologic, pancreatic cancers and related cancers.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama and 2 other locations · NCT07671937

• MRI scan for detecting pancreatic cancer in people at high risk

  This study tests a dedicated pancreas MRI (MRP) tool to see if it helps find pancreatic cancer earlier in people with a strong family or genetic risk.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07612046

• Cutting down ultra-processed foods for people at high cancer risk

  This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Avignon and 2 other locations · NCT07436312

• Carbon nanoparticle‑loaded iron for advanced solid tumors

  This test uses direct injections of a carbon nanoparticle‑loaded iron medicine (CNSI‑Fe) to see if it can shrink tumors in adults with advanced solid cancers who have no effective standard treatment options.

  Recruiting at 4 sites Phase 1/2 Sichuan Enray Pharmaceutical Sciences Company · Beijing, Beijing Municipality and 8 other locations · NCT07433283

• Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids

  This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.

  Recruiting at 2 sites Phase 2 HealthPartners Institute · Saint Louis Park, Minnesota and 1 other locations · NCT07354919

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.